FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200465963> ?p ?o ?g. }

• W4200465963 abstract "Abstract Aims Therapy with antineurohormonal drugs at target doses has a prognostic benefits in heart failure with reduced ejection fraction. Dilated cardiomyopathy (DCM) represents a particular setting where the possible benefit of target doses of antineurohormonal drugs is unexplored. Methods and results All patients enrolled from 1/1/1992 to 1/3/2020 in the Trieste Muscle Heart Disease register affected by DCM with data on the dosage of therapy available both enrollment and at follow-up visit (i.e., 6–12 month) were included. The population was divided according to the percentage of recommended dose prescribed (0–49%, 50–99%, 100%) of both renin-angiotensin system inhibitors (RASi) and beta blockers (BB). A composite of death/heart transplant/hospitalization for heart failure was considered as the primary endpoint; a composite of sudden cardiac death/major ventricular arrythmias/defibrillator intervention was evaluated as a secondary endpoint. Prognostic associations were explored with uni- and multivariate analyses, Cox regressions, Kaplan–Meier, cumulative incidence curves and propensity score matching. 826 patients were included. At baseline 789 (96%) were taking a RASi and 627 (76%) a BB. The target dose of RASi was prescribed in 29% and 36% of patients at enrolment and at follow-up visit, respectively. The percentage of patients taking the maximum recommended dose of BB was 10% at baseline and 17% after optimization. Predictors of reaching target dose for RASi were BMI &lt; 25 kg/m2, male sex [HR: 1.798 (95% CI: 1.073–3.012), P = 0.026] and higher systolic blood pressure [HR per mmHg 1.038 (95% CI: 1.025–1.051), P &lt; 0.001]. Target dose predictors of BB were age [HR per year 0.527 (95% CI: 0.347–0.802), P = 0.003] and highest systolic blood pressure [HR per mmHg 1.024 (95% CI: 1.013–1.035), P &lt; 0.001]. After adjustment target dose of RASi or BB did not show a significant association with the risk of primary outcome occurrence compared to those taking less than 50% (P = 0.550 for RASi and P = 0.921 for BB). The incidence of arrhythmic events was significantly lower in patients taking 100% of recommended dose of BB compared to those taking less than 50% (P = 0.009), after adjustment for confounders. The target dose of RASi was not associated with an arrhythmic events risk change (P = 0.688). Conclusions In DCM a significant number of patients do not tolerate maximal therapy doses, mainly due to hypotension. The achievement of the target dose of RASi and BB, after adjustment for confounders had a neutral effect on the incidence of heart failure-related events. Uptitration of BB to the recommended dose has a strong protective effect on arrhythmic events." @default.
• W4200465963 created "2021-12-31" @default.
• W4200465963 creator A5006194712 @default.
• W4200465963 creator A5012772336 @default.
• W4200465963 creator A5013585578 @default.
• W4200465963 creator A5014966655 @default.
• W4200465963 creator A5015026682 @default.
• W4200465963 creator A5024753725 @default.
• W4200465963 creator A5060589639 @default.
• W4200465963 creator A5062904345 @default.
• W4200465963 creator A5072068773 @default.
• W4200465963 date "2021-12-01" @default.
• W4200465963 modified "2023-09-27" @default.
• W4200465963 title "379 Contemporary use of guideline directed medical therapy in dilated cardiomyopathy: therapeutic optimization and prognostic benefits" @default.
• W4200465963 doi "https://doi.org/10.1093/eurheartj/suab139.029" @default.
• W4200465963 hasPublicationYear "2021" @default.
• W4200465963 type Work @default.
• W4200465963 citedByCount "0" @default.
• W4200465963 crossrefType "journal-article" @default.
• W4200465963 hasAuthorship W4200465963A5006194712 @default.
• W4200465963 hasAuthorship W4200465963A5012772336 @default.
• W4200465963 hasAuthorship W4200465963A5013585578 @default.
• W4200465963 hasAuthorship W4200465963A5014966655 @default.
• W4200465963 hasAuthorship W4200465963A5015026682 @default.
• W4200465963 hasAuthorship W4200465963A5024753725 @default.
• W4200465963 hasAuthorship W4200465963A5060589639 @default.
• W4200465963 hasAuthorship W4200465963A5062904345 @default.
• W4200465963 hasAuthorship W4200465963A5072068773 @default.
• W4200465963 hasBestOaLocation W42004659631 @default.
• W4200465963 hasConcept C126322002 @default.
• W4200465963 hasConcept C164705383 @default.
• W4200465963 hasConcept C168563851 @default.
• W4200465963 hasConcept C17923572 @default.
• W4200465963 hasConcept C203092338 @default.
• W4200465963 hasConcept C2776383484 @default.
• W4200465963 hasConcept C2778198053 @default.
• W4200465963 hasConcept C2778797674 @default.
• W4200465963 hasConcept C2908647359 @default.
• W4200465963 hasConcept C2911091166 @default.
• W4200465963 hasConcept C50382708 @default.
• W4200465963 hasConcept C71924100 @default.
• W4200465963 hasConcept C78085059 @default.
• W4200465963 hasConcept C84393581 @default.
• W4200465963 hasConcept C88879693 @default.
• W4200465963 hasConcept C99454951 @default.
• W4200465963 hasConceptScore W4200465963C126322002 @default.
• W4200465963 hasConceptScore W4200465963C164705383 @default.
• W4200465963 hasConceptScore W4200465963C168563851 @default.
• W4200465963 hasConceptScore W4200465963C17923572 @default.
• W4200465963 hasConceptScore W4200465963C203092338 @default.
• W4200465963 hasConceptScore W4200465963C2776383484 @default.
• W4200465963 hasConceptScore W4200465963C2778198053 @default.
• W4200465963 hasConceptScore W4200465963C2778797674 @default.
• W4200465963 hasConceptScore W4200465963C2908647359 @default.
• W4200465963 hasConceptScore W4200465963C2911091166 @default.
• W4200465963 hasConceptScore W4200465963C50382708 @default.
• W4200465963 hasConceptScore W4200465963C71924100 @default.
• W4200465963 hasConceptScore W4200465963C78085059 @default.
• W4200465963 hasConceptScore W4200465963C84393581 @default.
• W4200465963 hasConceptScore W4200465963C88879693 @default.
• W4200465963 hasConceptScore W4200465963C99454951 @default.
• W4200465963 hasIssue "Supplement_G" @default.
• W4200465963 hasLocation W42004659631 @default.
• W4200465963 hasOpenAccess W4200465963 @default.
• W4200465963 hasPrimaryLocation W42004659631 @default.
• W4200465963 hasRelatedWork W1984049176 @default.
• W4200465963 hasRelatedWork W2028591285 @default.
• W4200465963 hasRelatedWork W2153658479 @default.
• W4200465963 hasRelatedWork W2377979999 @default.
• W4200465963 hasRelatedWork W2386345027 @default.
• W4200465963 hasRelatedWork W2510270680 @default.
• W4200465963 hasRelatedWork W2600865675 @default.
• W4200465963 hasRelatedWork W3035006171 @default.
• W4200465963 hasRelatedWork W3108448879 @default.
• W4200465963 hasRelatedWork W3118940809 @default.
• W4200465963 hasVolume "23" @default.
• W4200465963 isParatext "false" @default.
• W4200465963 isRetracted "false" @default.
• W4200465963 workType "article" @default.